Current stock page

Stock Analysis

Nurix Therapeutics, Inc. (NRIX) Stock Analysis

Nurix Therapeutics, Inc. (NRIX) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.

NRIX Stock Analysis Summary

Nurix Therapeutics, Inc. (NRIX) currently has an AIQ Score of 65/100, indicating a bullish setup. Value is the strongest factor at 94/100. Risk is the weakest current factor at 40/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data

NRIX at a Glance

Crawlable current metrics from the latest market-close stock snapshot.

MetricCurrent
Price$15.48
AIQ Score65/100
Overall ViewBullish
Technical Analysis ConsensusStrong Sell
Market Cap$1.73B
P/E Ratio (TTM)6.17
Forward P/E—
EPS (Q3 FY2026)$4.93
Revenue (Q3 FY2026)$673.06M
Dividend Yield (TTM)0.00%
Beta1.06
Volume1.39M
52-week range$12.01-$28.23
RSI 1426.77
50-Day SMA$23.27
200-Day SMA$20.13
Analyst Price Target$33.63
Next EarningsJan 27, 2027
As of Nov 13, 2026 · Market close

NRIXNurix Therapeutics, Inc.

Healthcare / Biotechnology

Leader

Strong Relative Position

BullishEdge 8/10
$15.48−$0.12 (−0.77%)

Latest quote

  • Momentum
    50
  • Value
    94
  • Quality
    78
  • Risk resilience
    40
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

NRIX Stock Analysis Summary

Nurix Therapeutics, Inc. (NRIX) currently has an AIQ Score of 65/100, indicating a bullish setup. Value is the strongest factor at 94/100. Risk resilience is the weakest current factor at 40/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data
AIQ Composite Posture: Bullish

In a bullish regime, NRIX has AIQ Score of 65/100 with Value base of 94/100 and fading Risk resilience at 40/100. Wait for component alignment before adding exposure.

Signal Conflict Detected

Value (94/100) leads while Risk resilience (40/100) lags. This cross-factor spread creates entry timing uncertainty.

Healthcare · -0.77% stock move · NRIX classified in Biotechnology.

Current Evidence

BullishNRIX is in a bullish AIQ regime; Value is the strongest visible factor at 94/100.
Core coverage reflects visible evidence only

AlgovestIQ Evidence Summary

Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.

Is NRIX Bullish or Bearish Right Now?

NRIX currently has a bullish overall setup. Value is the strongest factor at 94/100, while Risk Resilience is weakest at 40/100. The current evidence suggests a constructive setup.

Bull Case
  • - Quality is supportive at 78/100.
  • - Analyst target implies +117.22% upside from the latest quote.
Bear Case
  • - Risk Resilience is weak at 40/100.
  • - Price is -23.09% below its 200-day SMA.
  • - Technical consensus has more sell votes than buy votes (37 vs 6).

Current Consensus

NRIX's Technical Analysis Consensus is currently Strong Sell, with 6 buy, 3 neutral, and 37 sell votes. NRIX's 14-day RSI is 26.77, which places the stock in an oversold momentum range. NRIX's beta is 1.06, indicating market sensitivity broadly in line with the market.

Signal Confidence
High agreement

What Changed in NRIX?

The largest recent change in NRIX is Momentum moving down by 25.0 points over the available 7-day comparison window. Value remains the strongest visible factor.

AIQ Score
-8.0
Momentum
-25.0
Quality
+1.0
Risk
+0.0

What Would Change the NRIX Outlook?

The current bullish outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.

Bullish confirmation

AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.

Bearish deterioration

AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.

NRIX Decision Framework

Public evidence layers, setup checks, and risk context for Nurix Therapeutics, Inc..

Nurix Therapeutics, Inc. (NRIX) Stock Analysis

Nurix Therapeutics, Inc. has an AIQ Score of 65/100 in a Bullish regime. Value is strongest at 94/100. Beta is 1.06, close to market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.

Evidence LayerPublic Evidence
Regime ContextNRIX is in a Bullish AIQ regime with score 65/100.
Signal ConflictThe primary conflict is that value leads at 94/100 while risk lags at 40/100.
Factor EvidenceMomentum 50/100 · Value 94/100 · Quality 78/100 · Risk 40/100
PersistenceCurrent snapshot evidence is shown; historical persistence remains in AIQ Pro.

Current Setup Checklist

Factor strengthPass

Value is the strongest factor at 94/100.

TimingWait

Momentum is 50/100 and RSI (14) is 26.8.

Regime fitPass

NRIX is in a Bullish regime at 65/100.

Risk controlFail

Risk factor is 40/100 with beta 1.06 and annual volatility 67.3%.

ConflictWait

Current conflict: value leads at 94/100 while risk lags at 40/100.

AIQ Score
65/100
Price
$15.48
Beta
1.06
RSI (14)
26.8

NRIX Research Cluster

Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.

NRIX Fundamentals

NRIX valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.

Revenue
$673.06M
Net income
$549.81M
Free cash flow
$614.24M
View full NRIX fundamental analysis

NRIX Technical Analysis

NRIX technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.

Technical Analysis Consensus
Strong Sell
RSI 14
26.77
Price vs SMA-50
-33.47%
View full NRIX technical analysis

NRIX Stock Catalysts

Track NRIX earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.

Next earnings
Jan 27, 2027
Analyst target
$33.63
News items
5
View NRIX earnings and stock catalysts

NRIX Dividend Analysis

NRIX dividend yield, annual dividend, payout ratio, payment history, and income reliability context.

Dividend yield
0.00%
Annual dividend
—
Payout ratio
—
View NRIX dividend history and analysis

NRIX Financial Data

NRIX revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.

Quarter revenue
$673.06M
EPS
$4.93
Periods
8
View NRIX financials

NRIX Risk Analysis

NRIX volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.

Beta
1.06
Risk score
40/100
1Y volatility
67.30%
View NRIX risk analysis

NRIX Stock News

NRIX stock news, market tone, recent headlines, and catalyst context.

News items
5
Updated
Nov 15, 2026
Sentiment
—
Read NRIX stock news

NRIX vs Biotechnology Peers

Current peer cohort: NRIX · NVAX · OCUL · OMER · ONC. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.

PeerAIQValueMomentumRiskSharpe1Y VolatilityCompare
NRIX
Current stock
65/10094/10050/10040/1000.6467.30%Current
NVAX
Novavax, Inc.
——77/10038/1000.5673.62%NRIX vs NVAX
OCUL
Ocular Therapeutix, Inc.
38/10041/10034/10036/100-0.4576.10%NRIX vs OCUL
OMER
Omeros Corporation
64/10073/10079/10033/1001.36110.84%NRIX vs OMER
ONC
BeOne Medicines AG
80/10071/10091/10072/1000.4234.16%NRIX vs ONC
Pairwise Compare links: NVAX · OCUL · OMER · ONCNRIX vs NVAXNRIX vs OCULNRIX vs OMERNRIX vs ONCCompare cohort

Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.

About the AIQ Score

Methodology for the current stock evidence.

As of Nov 13, 2026 · Market close

The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.

View AIQ methodology

Factor Diagnostics

A compact bridge from the AIQ score to the evidence tabs.

Calculator
Calculate a NRIX stock return scenario

Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.

Calculate stock return

Also for NRIX: historical return with reinvested dividends and stock average calculator for several buys.

AIQ Component Profile

Compare the five component scores on one consistent 0–100 scale.

Catalyst preview

Review earnings timing, revisions, news pressure, and prior event reactions in one place.

Open catalysts
Quarterly evidence

8 recent quarterly periods are available for review.

Checked Nov 16, 2026

AIQ Pro

Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.

Fundamentals Verdict

Current snapshot fields are separate from reported-quarter statement tables.

Current TTM P/E
6.17
As of Nov 13, 2026
Revenue growth
8426.27%
Gross margin
86.50%
Current debt / equity
0.07
Latest quarterly evidence

Latest period Aug 31, 2026.

Review fundamentals
Quarter revenue
$673.06M
Quarter net income
$549.81M
Quarter free cash flow
$614.24M

Market Confirmation

Technicals are summarized first, with the indicator library behind it.

Trend
Mixed
Momentum
Bearish
RSI 14
26.77
MACD
-2.48

Risk Alignment

Higher resilience is stronger; exposure metrics stay separate.

Resilience
40/100
Beta
1.06
Annual volatility
67.30%
Max drawdown
-46.60%

NRIX Stock FAQ

What is NRIX stock price today?

Nurix Therapeutics, Inc.'s current stock price is $15.48. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.

Is NRIX bullish or bearish right now?

NRIX's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.

What is NRIX's market cap?

NRIX's market cap is $1.73B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.

What is NRIX's current P/E ratio?

NRIX's current P/E ratio is 6.17 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.

What is NRIX's RSI?

NRIX's 14-day RSI is 26.77 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.

Is NRIX above its 50-day and 200-day moving averages?

NRIX is -33.47% from its 50-day SMA and -23.09% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.

When is NRIX's next earnings date?

NRIX's next earnings date is currently listed as Jan 27, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.

Does NRIX pay a dividend?

NRIX's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.